// App-Quantinova.ai

633 : Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC).

Researchers

Presenter

  • Neil M. Iyengar

Principal Investigators

  • Monica Nancy Fornier

  • Steven Sugarman

  • Diana Lake

  • Shanu Modi

  • Tiffany A. Traina

  • Melanie Chen

  • Sujata Patil

  • Jose Baselga

  • Larry Norton

  • Clifford A. Hudis

  • Gabriella D'Andrea

  • Pamela Drullinsky

  • Julie Fasano

  • Devika Gajria

  • Shari Beth Goldfarb

  • Elizabeth Anne Comen

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Congestive heart failure

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Pegfilgrastim

  • Trastuzumab

  • Paclitaxel

  • Lapatinib

Outcome

  • Negative

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01827163

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved